ArticleFrontiers in pharmacology2026
Impact of ARBs plus beta-blockers and other antihypertensives on cognitive impairment: a longitudinal study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertension is a major modifiable risk factor for dementia, yet the specific neuroprotective benefits of different antihypertensive drug classes remain unclear. This longitudinal population-based cohort study evaluated the association between various antihypertensive agents, used as monotherapy or combination therapy, and the risk of cognitive impairment. Methods: The present work is a retrospective cohort study based on electronic health records (EHR) provided by the Results: Loop diuretics and the combination of ARBs with beta-blockers, were associated with a reduced risk of cognitive impairment. Conversely, selective beta-blockers and angiotensin-converting enzyme (ACE) inhibitors were associated with an increased probability of impairment. Conclusion: Antihypertensive classes display divergent neuroprotective profiles. Loop diuretics, ARBs, and ARB-beta-blocker combinations appear protective, whereas ACE inhibitors and beta-blocker monotherapy show less favorable cognitive outcomes, highlighting the need for tailored pharmacological selection in aging populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.